#Geographic Atrophy Market Growth

[health-views-updates]

The Future of the Geographic Atrophy Market: Trends and Challenges

Geographic Atrophy Market Outlook, Scope & Overview:

Industry reports indicate that the geographic atrophy (GA) market is projected to grow at a CAGR of 7.2% over the forecast period 2023-2030.

Technological Advancements to Drive Growth of Global Geographic Atrophy Market

The adoption of advanced diagnostic and therapeutic solutions for geographic atrophy will continue to influence global market revenues. Healthcare providers and pharmaceutical companies are increasingly focusing on innovative treatments and early diagnosis methods to manage and treat geographic atrophy, a progressive and irreversible condition that leads to the degeneration of the retina.

As a treatment segment, emerging therapies currently hold a significant potential share of the global geographic atrophy market. This segment is anticipated to grow at a year-over-year rate of 7.2% over the forecast period, driven by the increasing prevalence of GA and the rising investment in research and development for effective therapies.

Get a Free Sample Report of Vitamins Market: https://www.snsinsider.com/sample-request/2480 

Geographic Atrophy Market Dynamics

Drivers:

The geographic atrophy market is witnessing significant growth due to the rising prevalence of age-related macular degeneration (AMD), of which GA is an advanced form. The growing elderly population, increasing awareness about retinal diseases, and the development of innovative treatment options are key factors driving the adoption of GA therapies worldwide. Additionally, advancements in imaging technologies and diagnostic tools are further propelling market growth by enabling early detection and intervention.

Restraints:

Despite the growth potential, challenges such as the high cost of emerging therapies, limited treatment options, and the complexity of clinical trials for GA are hindering the widespread adoption of geographic atrophy treatments. Moreover, the chronic nature of the disease and the need for long-term management pose additional challenges to market expansion.

Geographic Atrophy Market Outlook

The proven benefits of early diagnosis and innovative treatments in managing geographic atrophy have contributed to the market's growth. The geographic atrophy market is expected to witness increased adoption of advanced therapies across major healthcare markets, including North America, Europe, and Asia Pacific, driven by advancements in medical research and the growing focus on improving patient outcomes.

Global Geographic Atrophy Market

The rise in demand for geographic atrophy treatments in developed and emerging markets is expected to drive market growth over the forecast period. North America currently holds a significant market share in the global geographic atrophy market, with the US being a key contributor to market revenues. Europe and Asia Pacific regions are also experiencing rapid adoption of GA therapies, supported by favorable regulatory frameworks and increasing investments in healthcare infrastructure.

Key Players in the Geographic Atrophy Market

Leading companies in the geographic atrophy market include Apellis Pharmaceuticals, IVERIC bio, Roche, and Alkeus Pharmaceuticals. These companies are at the forefront of developing and commercializing advanced therapies and diagnostic tools for geographic atrophy, aiming to improve patient quality of life and slow disease progression.

In conclusion, the global geographic atrophy market is poised for steady growth over the forecast period, driven by technological advancements, increasing prevalence of retinal diseases, and the expanding adoption of innovative therapies and diagnostic solutions in managing geographic atrophy

Other Trending Reports

Nicotine Replacement Therapy Industry Growth

Dry Age-Related Macular Degeneration Industry Growth

Neurovascular Devices Industry Growth

Artificial Intelligence in Drug Discovery Industry Growth

[healthtech-katta]

Geographic Atrophy (GA) Market Expected to Grow at a CAGR of 7.2% Over the Forecast Period 2024-2032

Innovative Therapies and Rising Incidence of AMD to Drive Market Growth

The global Geographic Atrophy (GA) market is projected to experience steady growth at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2032. This growth is primarily driven by the increasing prevalence of age-related macular degeneration (AMD) and advancements in treatment options.

Rising Prevalence of Geographic Atrophy

Geographic Atrophy, an advanced form of AMD, affects millions of elderly individuals worldwide. As populations age, the incidence of GA is expected to rise, boosting demand for therapeutic solutions. According to market analysts, the growing elderly population and the higher awareness surrounding retinal diseases are key factors behind the projected market growth.

Get Free PDF Sample: https://www.snsinsider.com/sample-request/2480 

Emerging Treatments and Pipeline Advancements

In recent years, pharmaceutical companies have been making strides in developing innovative therapies for GA. The introduction of novel treatments, such as gene therapies and complement pathway inhibitors, offers hope for slowing disease progression. These advancements are expected to accelerate market expansion during the forecast period.

North America Leading the Charge, Asia-Pacific to See Rapid Growth

North America currently dominates the Geographic Atrophy market, driven by significant investment in research and healthcare infrastructure. Meanwhile, the Asia-Pacific region is expected to witness the fastest growth rate due to increasing healthcare spending, improved diagnostic capabilities, and a rising geriatric population.

Outlook for 2032 and Beyond

With the increasing prevalence of GA and continuous innovation in treatment options, the market is poised for strong growth through 2032. Pharmaceutical companies are expected to focus on expanding their pipelines, with potential breakthrough therapies on the horizon, setting the stage for a dynamic market in the coming decade.

[wellnessweb]

Innovative Strategies: Impacting Spinal Muscular Atrophy Treatment Market Size

The Spinal Muscular Atrophy Treatment Market size was estimated USD 4.2billion in 2022 and is expected to reach USD 7.1 billion by 2030 at a CAGR of 6.9% during the forecast period of 2023-2030.In the dynamic landscape of healthcare, the Spinal Muscular Atrophy (SMA) treatment market emerges as a beacon of hope, characterized by a convergence of groundbreaking therapies and innovative approaches. With a keen focus on addressing the underlying genetic mutations responsible for this debilitating neuromuscular disorder, the market showcases a diverse array of treatment modalities ranging from gene replacement therapies to small molecule interventions. Pioneering advancements in gene editing technologies, such as CRISPR-Cas9, have spurred a new wave of precision medicine, offering tailored solutions to patients across varying disease severities. Additionally, collaborative efforts between pharmaceutical companies, research institutions, and advocacy groups have propelled clinical trials forward, accelerating the pace of therapeutic development. As the therapeutic landscape continues to evolve, driven by a commitment to improving patient outcomes and quality of life, the SMA treatment market stands as a testament to the transformative power of scientific innovation and collective perseverance.

Get Sample Of This Report @ https://www.snsinsider.com/sample-request/3384

Market Scope & Overview

The research looks into the major variables affecting the expansion of the global market. The report used a bottom-up approach to gather and forecast data for a wide range of industrial verticals and end-user industries, as well as their reach across several categories, in order to determine the overall size of the Spinal Muscular Atrophy Treatment Market throughout the forecast period. Market actors may use market data to create plans to improve their competitive position.

The Spinal Muscular Atrophy Treatment Market research report covers all of these topics in great detail, including the Porter's Five Forces analysis, significant segments, drivers, opportunities, and the competitive environment. For business experts, stakeholders, investors, VPs, and newcomers who want to learn more about the company and formulate a competitive strategy, this study is an excellent resource.

Market Segmentation Analysis

By Type

Type 1

Type 2

Type 3

Type 4

By Treatment

Gene Therapy

Drug

By Drug

Spinraza

Zolgensma (AVXS-101)

Evrysdi

Others

By Route of Administration

Oral

Injection

COVID-19 Impact Analysis

Due to the COVID-19 lockout, it was necessary to create original strategies for dealing with future occurrences while sustaining steady growth. The market research report also provides advice for overcoming pandemic-like situations and lessening their harmful effects. The Spinal Muscular Atrophy Treatment Market was significantly impacted by the COVID-19 epidemic. Due to delays in new developments, the industry has also been suspended internationally.

Regional Outlook

With a focus on North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa, the Spinal Muscular Atrophy Treatment Market  research report digs into market aspects including estimations for total price from top manufacturers and trends toward advancement in various regions of the world.

Competitive Analysis

The research report offers a complete analysis of the worldwide Spinal Muscular Atrophy Treatment Market and suggests important adjustments that market players should take into account when developing their business plans. To gain market dominance, these companies have used partnerships, product development, joint ventures, mergers and acquisitions, diversification, and joint ventures.

Key Reasons to Purchase Spinal Muscular Atrophy Treatment Market Report

To identify important geographic regions and leading nations that have a substantial impact on market revenue, the researchers conduct geographic study.

Prospect information may be used by market participants to evaluate potential and formulate their next moves.

Report Conclusion

Manufacturers, distributors, dealers, and policymakers may use the data from the market research report to assess which industry sectors should be prioritized in the upcoming years in order to plan investments and take advantage of the Spinal Muscular Atrophy Treatment Market expansion.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Diabetic Neuropathy Market Trends

Smart Contact Lenses Market Size Trends

Lymphoma Treatment Market Trends

Veterinary Vaccine Adjuvants Market Trends

Medical Electrodes Market Trends

[conversationpoint]

Geographic Atrophy Market Anticipated Growth by 2032, as Predicted by DelveInsight | Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences

http://dlvr.it/T5ZRmK

[rohans18]

Postmenopausal Vaginal Atrophy Treatment Market Expected High Growth in Coming Years

Global Postmenopausal Vaginal Atrophy Treatment Market, By Therapy Type (Estrogen based drugs, Non-estrogen based drugs and Others), Drug Form (Vaginal gel, Creams, Tablet and Others), Route of Administration (Oral, Intravaginal and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.In the consistent Postmenopausal Vaginal Atrophy Treatment market research report, industry trends are put together on macro level with which clients can figure out market landscape and possible future issues about Postmenopausal Vaginal Atrophy Treatment industry. The scope of this market report include but is not limited to latest trends, market segmentation, new market entry, industry forecasting, future directions, opportunity identification, strategic analysis and planning, target market analysis, insights and innovation. The report presents with the CAGR value fluctuations for the specific forecasted period which helps decide costing and investment strategies. An influential Postmenopausal Vaginal Atrophy Treatment market report brings precise and exact market research information that drives business into the right direction.

Key Players

Aragen Life Sciences Pvt. Ltd. (India)

Selexis SA (Switzerland)

Merck KGaA (Germany)

CELONIC Group (Switzerland)

Promega Corporation (U.S.)

JSR Life Sciences, LLC (U.S.)

trenzyme GmbH (Germany)

Thermo Fisher Scientific Inc. (U.S.)

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-postmenopausal-vaginal-atrophy-treatment-market

The research studies entailed in the winning Postmenopausal Vaginal Atrophy Treatment market report supports to estimate several important aspects that includes but are not limited to investment in a rising market, success of a new product, and expansion of market share. The strategies underlined here mainly consist of new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others that boost footprints in this market. Several other factors such as import, export, gross margin, price, cost, and consumption are also analyzed under the section of production, supply, sales and market status.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Postmenopausal Vaginal Atrophy Treatment Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Enzyme-Linked Immunospot Assays Market

FluoroSpot Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

[desmoinesnewsdesk]

Geographic Atrophy Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Ionis, Roche, NGM Biopharma, Apellis Pharma, Novartis, Genentech

http://dlvr.it/SmjbDf

[technewspoint]

Geographic Atrophy Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Ionis, Roche, NGM Biopharma, Apellis Pharma, Novartis, Genentech

http://dlvr.it/SmjbDW

[thesunshinereporter]

Geographic Atrophy Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Ionis, Roche, NGM Biopharma, Apellis Pharma, Novartis, Genentech

http://dlvr.it/SmjbB2

[columbianewsupdates]

Geographic Atrophy Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Ionis, Roche, NGM Biopharma, Apellis Pharma, Novartis, Genentech

http://dlvr.it/Smjb1w

[health-views-updates]

Antiepileptic Drugs Market Predictions: Future Insights and Analysis

Antiepileptic Drugs Market Outlook, Scope & Overview:

Industry reports indicate that the global antiepileptic drugs market was valued at USD 18.21 billion in 2023 and is projected to reach USD 26.30 billion by 2031, growing at a CAGR of 4.70% over the forecast period 2024-2031.

Technological Advancements to Drive Growth of Global Antiepileptic Drugs Market

The adoption of advanced antiepileptic drugs (AEDs) will continue to influence global market revenues. The increasing prevalence of epilepsy and other seizure disorders, along with ongoing advancements in drug development and therapy options, are expected to drive market growth.

As a product segment, novel AEDs currently hold a significant share of the global antiepileptic drugs market. This segment is anticipated to grow at a year-over-year rate of 4.70% in 2024 over 2023 and reach USD 26.30 billion in revenues by 2031. The growing demand for effective and targeted therapies, along with increasing awareness about epilepsy, is expected to drive market growth.

Get a Free Sample Report: https://www.snsinsider.com/sample-request/3124

Antiepileptic Drugs – Market Dynamics

Drivers:

The antiepileptic drugs market is witnessing growth due to the rising incidence of epilepsy and the need for effective treatment options. Advances in drug research and development, including the introduction of novel AEDs with improved efficacy and safety profiles, are key factors driving market expansion. Additionally, the increasing adoption of personalized medicine approaches and the growing focus on patient-centric therapies are further propelling market growth.

Restraints:

Despite the growth potential, challenges such as high treatment costs, side effects associated with some AEDs, and the complexity of managing chronic conditions can hinder the widespread adoption of antiepileptic drugs. Moreover, regulatory hurdles and the need for ongoing research to address unmet medical needs pose additional challenges to market expansion.

Antiepileptic Drugs – Market Outlook

The proven benefits of antiepileptic drugs in managing seizure disorders and improving patient quality of life have contributed to the market's growth. Antiepileptic drugs are expected to witness increased adoption across major markets, including North America, Europe, and Asia Pacific, driven by advancements in drug development and the growing focus on epilepsy management.

Global Antiepileptic Drugs Market

The rise in demand for antiepileptic drugs in developed and emerging markets is expected to drive market growth over the forecast period. North America currently holds a significant market share in the global antiepileptic drugs market, with the US being a key contributor to market revenues. Europe and Asia Pacific regions are also experiencing growth in the adoption of AEDs, supported by increasing healthcare investments and rising awareness about epilepsy.

Key Players in the Antiepileptic Drugs Market

Leading companies in the antiepileptic drugs market include Pfizer Inc., Novartis International AG, Johnson & Johnson, and GlaxoSmithKline plc. These companies are at the forefront of developing and commercializing advanced AEDs for various types of epilepsy and seizure disorders.

In conclusion, the global antiepileptic drugs market is poised for steady growth over the forecast period, driven by technological advancements, increasing prevalence of epilepsy, and the expanding adoption of novel and effective therapies for seizure management.

Other Trending Reports

Magnetic Resonance Imaging (MRI) Industry Growth

Infusion Pump Software Industry Growth

Military Wearable Medical Device Industry Growth

Geographic Atrophy (GA) Industry Growth

[thealphareporter]

Geographic Atrophy Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Ionis, Roche, NGM Biopharma, Apellis Pharma, Novartis, Genentech

http://dlvr.it/SmjYmt

[newsheadlinesnow]

Geographic Atrophy Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Ionis, Roche, NGM Biopharma, Apellis Pharma, Novartis, Genentech

http://dlvr.it/SmjYLd

[rohans18]

Postmenopausal Vaginal Atrophy Treatment Market Growth, Segments, Demand and Forecast to 2030

Global Postmenopausal Vaginal Atrophy Treatment Market, By Therapy Type (Estrogen based drugs, Non-estrogen based drugs and Others), Drug Form (Vaginal gel, Creams, Tablet and Others), Route of Administration (Oral, Intravaginal and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

An expert team performs systematic, object-oriented and complete market research study to provide the facts associated with any subject in the field of marketing via Postmenopausal Vaginal Atrophy Treatment marketing report. The report has a lot to offer to both established and new players in the Postmenopausal Vaginal Atrophy Treatment industry with which they can completely understand the market. SWOT analysis and Porter’s Five Forces analysis methods are used wherever applicable, while generating this report. One of the most important parts of an international Postmenopausal Vaginal Atrophy Treatment market report is competitor analysis with which businesses can estimate or analyse the strengths and weaknesses of the competitors.

Key Players

Novartis AG (Switzerland)

Hikma Pharmaceuticals plc (U.K.)

Aurobindo Pharma (India)

AbbVie Inc. (U.S.)

Melinta Therapeutics, Inc (U.S.)

Bristol-Myers Squibb Company (U.S.)

GSK plc. (U.K.)

Bayer AG (Germany)

Lupin (India)

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-postmenopausal-vaginal-atrophy-treatment-market

With the help of credible Postmenopausal Vaginal Atrophy Treatment market analysis report, businesses can make out the reaction of the consumers to an already existing product in the market. The report includes estimations of recent state of the market, CAGR values, market size and market share, revenue generation, and necessary changes required in the future products. A wide-ranging competitor analysis helps build superior strategies of production, improvement in certain product, its advertising or marketing and promotion for the business. Exhaustive and comprehensive market study performed in the wide ranging Postmenopausal Vaginal Atrophy Treatment market report offers current and forthcoming opportunities that put light on the future market investment.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Postmenopausal Vaginal Atrophy Treatment Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Enzyme-Linked Immunospot Assays Market

Postmenopausal Vaginal Atrophy Treatment Market

Clinical Microbiology Market

Nephrology And Urology Devices Market

Artificial Ventilation Market

FluoroSpot Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sales@databridgemarketresearch.com

[marketinsightshare]

Neurodegenerative Disease Market - Forecast(2022 - 2027)

The Neurodegenerative Disease Market size is estimated to reach $49,218 million by 2027. Furthermore, it is poised to grow at a CAGR of 3.9% over the forecast period of 2022-2027. Neurodegenerative diseases are a set of brain disorders that cause the structure and function of neurons in the central nervous system (CNS) and peripheral nervous system (PNS) to deteriorate over time (PNS). Several drugs are currently available to help people lessen physical or mental symptoms and improve their quality of life. Furthermore, researchers are concentrating their efforts on developing molecular diagnostics, particularly biomarkers and imaging spectroscopy, in order to detect and diagnose neurodegenerative illnesses at an early stage and halt their progression. The impact of COVID-19 on the neurodegenerative disease market is projected to be significant, as the pandemic has disrupted clinical trial, research and development, and pipeline product workflows, resulting in relatively modest growth during the pandemic despite a solid late-stage product pipeline. Despite the pandemic the market is forecasted to gradually recover and grow in the years of forecast. The companies with higher funding and revenue are investing more into R&D with development of unique neurodegenerative disease drugs for the various neurodegenerative indications while expanding to new geographic locations through its sales channel expansion. Recently, companies are focusing on making continuous investment across the business to in order to build and maintain the pipeline of new drugs for therapeutics. Companies are also predicted to acquire, grow the foreign market revenue and continue to get timely regulatory approvals. Rising prevalence of Alzheimer disease, increasing public awareness, and a strong product pipeline for neurodegenerative disease treatment are some of the factors driving the drug Industry forward in the projected period of 2022-2027.

Report Coverage

The report: “Neurodegenerative Disease Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Neurodegenerative Disease Market.

By Drug Class- N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Acetylcholinesterase (AChE) Inhibitors, Dopamine Agonists and Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor.

By Indications- Parkinson’s Disease, Huntington Disease, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Spinal Muscular Atrophy (SMA) and Others.

By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

Geographically, North America held a dominant market share in the year 2021. The growing geriatric population in the US is increasing the prevalence of neurodegenerative diseases as age is the best known risk factor for such diseases. The geriatric population was estimated to be around 65 million in 2020. This is projected to increase by 18 million between 2020 and 2030 and it is estimated that approximately 1 in every 5 Americans will be 65 or more by 2030..

The surge in neurodegenerative diseases in the US owing to the rising geriatric population is increasing the demand for effective neurodegenerative disease therapies for treating the disease and suppressing symptoms. In addition, it has also resulted in an increase in public R&D expenditure towards drug research, which will further contribute to the market growth. For instance, the Federal Alzheimer's and Dementia Research Funding increased from $2.8 billion in 2019 to $3.2 in 2021.

A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Neurodegenerative Disease Market Report.

Neurodegenerative Disease Market- Geography (%) for 2021

For More Details on This Report - Request for Sample

Neurodegenerative Disease Market Segmentation Analysis- By Drug Class

The neurodegenerative disease market based on drug class can be further segmented into N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Acetylcholinesterase (AChE) Inhibitors, Dopamine Agonists and Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor. Immunomodulators held a dominant market share in the year 2021. Immunomodulators provides very effective therapy options for a variety of autoimmune and neurodegenerative illnesses. Furthermore, the growing presence of important companies is likely to raise patient and physician awareness of the benefits of immunomodulators. As they strive to obtain a competitive advantage in the market, they are developing novel immunomodulators to treat a variety of chronic conditions.

However, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors is estimated to be the fastest-growing, with a CAGR of 13.3% over the forecast period of 2022-2027. It is owing to increase in number of patients with bipolar diseases, schizophrenia, and Huntington’s disease and other neuropsychiatric disorders undergoing long-term medical treatments with antipsychotic medication. Furthermore, throughout the projected period, investigational research for the discovery of novel therapies using VMAT2 inhibitors to treat Huntington disease are expected to drive demand.

Neurodegenerative Disease Market Segmentation Analysis- By Indications

The neurodegenerative disease market based on indications can be further segmented into Parkinson’s Disease, Huntington Disease, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Spinal Muscular Atrophy (SMA) and Others. Multiple Sclerosis held a dominant market share in the year 2021. Recently, more than 4,00,000 people in U.S. are suffering from multiple sclerosis which is rising the adoption of various types of drug class, so the demand for neurodegenerative drugs is expanding. Apart from this, the breakout of the COVID-19 pandemic has had a significant impact on the growth of the multiple sclerosis medications, as it has disrupted the supply chains of numerous important participants in the industry. For example, Biogen announced that sales of one of its important medications, TECFIDERA, which is used to treat multiple sclerosis, fell by 13% in 2020 compared to the previous year such factors are predicted to have a minor impact on market expansion.

However, Huntington Disease is estimated to be the fastest-growing, with a CAGR of 13.2% over the forecast period of 2022-2027. It is owing to various factors such as greater adoption of novel drugs, expanded R&D activity, an increase in the target population, and supportive regulatory measures are all driving the Huntington's Disease incidence. Reportedly, more than 20 drugs are in various phases of clinical trials for the treatment of Huntington's disease.

Neurodegenerative Disease Market Segmentation Analysis- By Geography

The neurodegenerative disease market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 3.1% in the year 2021 as compared to the other counterparts. It is owing to increasing prevalence of neurodegenerative diseases such as Alzheimer diseases, Huntington disease etc. According to the Centers for Disease Control (CDC), Alzheimer's disease is the 6th leading cause of death among US adults. In 2020, it is estimated that more than 5.8 million Americans aged 65 years or older are suffering from Alzheimer’s disease. This is projected to reach 7.7 million by 2030. Meanwhile, according to the Parkinson’s Foundation Prevalence Project, the prevalence of Parkinson’s in the US is predicted to rise from 930,000 in 2020 to 1.2 million by 2030.

Neurodegenerative Disease Market Drivers

Rising prevalence of Alzheimer disease have readily aided the market growth

Alzheimer's disease is a degenerative neurological disease and the most common form of dementia, characterised by memory loss, loss of thinking skills, and difficulties with problem-solving and language. Alzheimer's disease symptoms appear gradually over many years and eventually grow more severe. According to the World Health Organization (WHO), in 2021 over 50 million individuals suffer from dementia, a frequent form of Alzheimer's disease, with 10 million new cases diagnosed each year. The increased prevalence of these disorders also drives the development of various medications. Besides, the market is growing as people become more aware of the drug therapies for Alzheimer's disease around the world. Furthermore, rising awareness of the different novel treatment alternatives, is also helping to fuel the rise of Alzheimer's Drugs.

Availability of robust pipeline of drugs for neurodegenerative disease treatment is driving the market growth

Availability of robust pipeline of drugs for neurodegenerative disorders is forecasted to drive growth of the global Neurodegenerative Disease Market. Recently, in 2021, GlaxoSmithKline Plc in collaboration with Alector Inc. to develop antibody-based treatments for Parkinson's, Alzheimer's and other similar diseases. This collaboration deals worth up to $2.2 billion which efforts to build a robust pipeline of drugs.

Neurodegenerative Disease Market Challenges

High cost of treatment are some of the factors impeding the market growth

The extremely high cost is anticipated to hamper market growth as it limits the access of quality treatment to the middle and low-income population countries. For instance, in U.S. the average annual medical cost for the treatment of Multiple Sclerosis (MS) can reach more than $70,000. This is highly expensive as the country’s median household income in 2020 was only $67,521.

Neurodegenerative Disease Market Competitive Landscape

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Neurodegenerative Disease Market. The top 10- Neurodegenerative Disease Market companies are-

Biogen Inc.,

F. Hoffman La Roche Ltd.,

Merck KGaA,

Novartis AG,

Sanofi,

Teva Pharmaceuticals Industries Ltd.,

Orion Corporation,

H. Lundbeck A/S.,

Sun Pharmaceutical Industries Ltd.,

UCB S.A.

Recent Developments

In May 2021, Biogen Inc. and Envisagenics announced a new collaboration to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases. As part of the collaboration, Biogen will leverage Envisagenics’ proprietary artificial intelligence (AI)-driven RNA splicing platform, SpliceCore®, to define and understand the regulation of different RNA isoforms in CNS cell types.

In August 2020, Roche announced that the U.S. Food and Drug Administration (FDA) has approved Evrysdi�� (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older. This is predicted to drive the SMA indication segment.

In February 2020, Novartis announced that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company’s Supplemental Biologics License Application (sBLA) and Marketing Authorization Application (MAA), respectively, for ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults.